Predictive Factors of Prostatic Cancer Detection on Repeat Prostate Biopsy.
- Author:
Sung Ho RYU
1
;
Soo Eung CHAI
;
Han Yong CHOI
Author Information
1. Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. hychoi@smc.samsung.co.kr
- Publication Type:Original Article
- Keywords:
Prostate biopsy;
Prostate cancer;
Predictive factor
- MeSH:
Biopsy*;
Humans;
Male;
Prostate*;
Prostate-Specific Antigen;
Prostatic Intraepithelial Neoplasia;
Prostatic Neoplasms*;
Ultrasonography
- From:Korean Journal of Urology
2003;44(1):1-5
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To determine the demographic and tumor related predictors of repeat biopsy cancer detection in men diagnosed with benign prostatic tissue following an initial prostate biopsy. We evaluated the clinical parameters of prostate cancers detected on repeat biopsy. MATERIALS AND METHODS: Between May 1994 and 2001, 1,016 patients with suspected prostatic cancer underwent a transrectal ultrasound guided prostate biopsy. Of the 721 patients whose biopsy specimens were negative for prostate cancer, 53 had a repeat prostate biopsy for persistently, or abruptly elevated, prostate specific antigen (PSA) values. We examined their serum PSA, PSA density, free to total PSA value, annualized interbiopsy PSA change and biopsy core numbers, as well as their age, prostate size and the histological results of their initial, and repeated, biopsies, to determine if any predictor of the need for a repeat biopsy could be identified. RESULTS: From the repeat biopsies, 15 patients (28.3%) had prostate cancer. There were significant differences between the benign and malignant repeat biopsies, in relation to PSA density (p=0.001), free to total PSA value (p=0.002) and annualized interbiopsy PSA change (p=0.001). No patient with high-grade prostatic intraepithelial neoplasia was subsequently found to have cancer. CONCLUSIONS: The PSA density, free to total PSA value and annualized interbiopsy PSA change appear to aid in the prediction of cancer on a repeat biopsy.
